Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 5Neoplasm Metastasis 2Vomiting 1Urinary Bladder Neoplasms 1TP53 Y220C Mutation 1Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Cancer 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 72Cytarabine 46fludarabine phosphate 45fludarabine 42Vincristine 29Filgrastim 27Peripheral Blood Stem Cell Transplantation 25Methotrexate 25Etoposide 24Dexamethasone 23Melphalan 21Rituximab 20Doxorubicin 19Clofarabine 19Tacrolimus 17Mycophenolic Acid 17Dasatinib 16Bortezomib 15Whole-Body Irradiation 14Vorinostat 14pegaspargase 13Cyclosporine 13Calcium Dobesilate 13Busulfan 13Antilymphocyte Serum 12tanespimycin 10Topotecan 10Stem Cell Transplantation 10Specimen Handling 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tablets × Clear all
NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Nova Laboratories Limited

Phase 1 Completed
70 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡